Product name as reported
Bydureon: adverse event reports filed with FDA
19,492 reports list it as a suspect or interacting product, 2006–2026.
- 19,492
- reports as suspect product
- 0.1% of all reports · about 971 a year
- 6
- reports, 12 months to June 2026
- 57 in the 12 months before
- 20.2%
- marked serious by the reporter
- 57.4% across all reports
- 1.4%
- record death among outcomes, as reported
- 266 reports · not verified by FDA
Between June 2006 and February 2026, 19,492 adverse event reports received by FDA list the product name "Bydureon" as reporters wrote it as a suspect or interacting product. Reports that mention it only as a concomitant medication (1,972) are left out of every figure here.
In the 12 months to June 2026, 6 reports listed it, down 89% from 57 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 971 reports a year and 0.1% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded injection site haemorrhage (16%), injection site pain (15.9%) and injection site mass (12.2%). A report can list several reactions, so shares add to more than 100%; 1,003 different terms appear across these reports. Injection site haemorrhage is recorded in 16% of these reports, against 0.4% of all reports in the database.
20.2% of the reports are marked serious by the reporter; 1.4% record death among the outcomes and 7.9% record hospitalisation, as reported. 60.6% of the reports came from consumers, and the largest patient age group is 45 to 64 (28.5%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Bydureon reports recording the termall reports in the database
- Injection site haemorrhagebleeding where the injection was given16%3,121
- Injection site painpain where the injection was given15.9%3,103
- Injection site mass12.2%2,377
- Injection site nodule11.2%2,184
- Blood glucose increasedraised blood sugar reading10.9%2,118
- Weight decreasedweight loss10.1%1,966
- Nauseafeeling sick9.1%1,779
- Product quality issuea problem with the product itself8%1,569
- Injection site extravasation7.5%1,469
- Device malfunctionthe device did not work properly7.3%1,432
- Underdoseless than the intended dose7.1%1,385
- Device leakagethe device leaked7.1%1,376
- Device issuea problem with the device6.4%1,250
- Injection site pruritusitching where the injection was given6.2%1,209
- Drug dose omissiona dose was missed5.1%993
- Intentional product misusedeliberate use not as intended4.8%931
- Vomitingbeing sick4.4%858
- Incorrect dose administered by devicethe device gave the wrong dose4.2%826
- Diarrhoealoose or frequent stools4.1%792
- Injection site bruisingbruising where the injection was given4%770
- Decreased appetitereduced appetite3.9%760
- Needle issuea problem with the needle3.9%758
- Injection site erythemaredness where the injection was given3.8%747
- Wrong technique in product usage processthe product was used in the wrong way3.2%624
- Intentional device misuse3.1%610
- Injection site swellingswelling where the injection was given3.1%598
- Incorrect dose administeredthe wrong dose was given3%588
- Off label useused for a purpose or in a way not on the label3%580
- Malaisegeneral feeling of being unwell2.9%575
Top 30 of 1,003 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 94.7% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Type 2 diabetes mellitus | 10,817 | 55.5% |
| Diabetes mellitus | 1,824 | 9.4% |
| Blood glucose abnormal | 185 | 0.9% |
| Glycosylated haemoglobin increased | 160 | 0.8% |
| Blood glucose increased | 115 | 0.6% |
| Glucose tolerance impaired | 73 | 0.4% |
The indication field is filled in by the reporter and is often blank; shares are of all 19,492 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Bydureon reports |
|---|---|---|
| Metformin | 4,691 | 24.1% |
| Bydureon Bcise | 2,268 | 11.6% |
| Byetta | 1,497 | 7.7% |
| Lisinopril | 1,321 | 6.8% |
| Lantus | 1,257 | 6.4% |
| Aspirin | 891 | 4.6% |
| Glipizide | 844 | 4.3% |
| Glimepiride | 834 | 4.3% |
| Atorvastatin | 684 | 3.5% |
| Insulin | 558 | 2.9% |
Other products listed in reports where Bydureon is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Bydureon | All reports |
|---|---|---|
| Reports as suspect product | 19,492 | 20,646,523 |
| Share of that pool | — | 0.1% |
| Reports, latest 12 months | 6 | 1,332,454 |
| Marked serious | 20.2% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 14 | 91 |
| Hospitalisation recorded, per 1,000 reports | 79 | 213 |
| Consumer-filed share | 60.6% | 45.8% |
| Top term, share of reports | Injection site haemorrhage 16% | 0.4% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Bydureon reports
How many adverse event reports has FDA received for Bydureon?
19,492 reports list Bydureon as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 6 of them arrived in the latest 12 months. Another 1,972 list it only as a concomitant medication.
What reactions are recorded in Bydureon reports?
injection site haemorrhage (16%), injection site pain (15.9%), injection site mass (12.2%), injection site nodule (11.2%) and blood glucose increased (10.9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Bydureon was responsible.
How serious are the reports?
20.2% are marked serious by the reporter. Among the outcomes recorded, 1.4% of reports include death and 7.9% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (60.6%), not given (21.9%) and physician (11.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Bydureon rising?
6 reports in the 12 months to June 2026, down 89% from 57 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Bydureon was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Bydureon?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Bydureon as a suspect or interacting product; reports listing it only as a concomitant medication (1,972) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.